Rivastigmine Tartrate Capsule
NDC Package 65862-649-39
Package Information
Rivastigmine Tartrate capsules is rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. This formulation utilizes a capsule delivery system. Marketed by Aurobindo Pharma Limited, this product is identified by NDC 65862-649 and is authorized under FDA application ANDA204572.
Identification & Billing
- RxCUI: 312835 - rivastigmine tartrate 3 MG Oral Capsule
- RxCUI: 312835 - rivastigmine 3 MG Oral Capsule
- RxCUI: 312835 - rivastigmine 3 MG (as rivastigmine tartrate) Oral Capsule
- RxCUI: 312836 - rivastigmine tartrate 6 MG Oral Capsule
- RxCUI: 312836 - rivastigmine 6 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 65862 - Aurobindo Pharma Limited
- 65862-649 - Rivastigmine Tartrate
- 65862-649-39 - 3000 CAPSULE in 1 BAG
- 65862-649 - Rivastigmine Tartrate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (65862-649). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 65862-649-39 identifies a specific commercial package of 3000 capsule in 1 bag of Rivastigmine Tartrate, a human prescription drug labeled by Aurobindo Pharma Limited. This capsule is formulated for oral use and contains rivastigmine tartrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aurobindo Pharma Limited on March 25, 2016. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.
How is this Aurobindo Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 65862064939. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.